the patient had an unexpected gastric hemorrhage and died. Autopsy showed acute ul-cerative gastric lesions; no findings other than those correlated with chronic uremia were present. The involvement of nifedipine in this case of agranulocytosis is indicated by the pattern of myeloid damage (suggesting a toxic origin) and by the prompt recovery of the bone marrow after stopping nifedipine administration. We have also considered the fact that the patient had received nifedipine during the previous 2 years without any side effects. This delayed reaction could be explained by the fact that the patient did not receive nifedipine during treatment for the myocardial infarction, and that the nifedipine therapy was reassumed after treatment with a DNA synthesis inhibitor, acyclovir. Since there is considerable evidence of the significant role played by calcium in regulating the mytotic process [4] [5] [6] , the possibility that the previous treatment with acyclovir facilitated the development of agranulocytosis during nifedipine administration cannot be ruled out. On the other hand, no case of agranulocytosis due to acyclovir has been reported and this drug was administrated for only a few days 2 months before the appearance of the myeloid involvement. Agranulocytosis during Nifedipine Treatment in a Hemodialysis Patient 307
